{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:20:42Z","timestamp":1790803242171,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ijrobp.2022.07.002","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T03:36:03Z","timestamp":1657942563000},"page":"812-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Salvage (Re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer"],"prefix":"10.1016","volume":"114","author":[{"given":"Supriya","family":"Chopra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babusha","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaahid","family":"Mulani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevanshu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Gurram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitali","family":"Alone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Gulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.07.002_bib0001","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without Paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study","volume":"22","author":"Moore","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0002","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0003","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0004","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0005","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0006","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2011.05.040","article-title":"Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study","volume":"122","author":"Santin","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2009.07.024","article-title":"A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A Gynecologic Oncology Group Study","volume":"115","author":"Fiorica","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0008","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jjco\/hyw143","article-title":"A single-arm study evaluating bevacizumab, cisplatin, and Paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer","volume":"47","author":"Sugiyama","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0009","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/IGC.0000000000001216","article-title":"The European Society of Gynaecological Oncology\/European Society for Radiotherapy and Oncology\/European Society of Pathology guidelines for the management of patients with cervical cancer","volume":"28","author":"Cibula","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0010","first-page":"1","article-title":"National Cancer Grid of India Consensus Guidelines on the management of cervical cancer","author":"Chopra","year":"2018","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0011","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0012","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"KEYNOTE-826. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0013","article-title":"Cost effectiveness of bevacizumab plus chemotherapy for the treatment of advanced and metastatic cervical cancer in India: A model-based economic analysis","volume":"8","author":"Gupta","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0014","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligo-metastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2020.10.037","article-title":"Management of oligo-metastatic and oligorecurrent cervical cancer: A pattern of care survey within the EMBRACE research network","volume":"155","author":"Chopra","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0016","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/COC.0b013e3182610878","article-title":"Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer","volume":"37","author":"Jereczek-Fossa","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0017","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0018","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/ijmr.IJMR_298_21","article-title":"Role of radiation therapy in oligometastatic and oligorecurrent cervical cancer","volume":"154","author":"Mangaj","year":"2021","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0020","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ijrobp.2022.04.046","article-title":"Dose accumulation for multicourse gynecological reirradiation: A methodological narrative and clinical examples","volume":"113","author":"Mulani","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0021","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2015.02.027","article-title":"A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0022","first-page":"3","article-title":"Patterns of first relapse and outcome in patients with locally advanced cervical cancer after radiochemotherapy: A single institutional experience","volume":"18","author":"Sasidharan","year":"2020","journal-title":"Indian J Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0023","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2020.01.001","article-title":"The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population","volume":"157","author":"Jordan","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0024","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaoncol.2018.2677","article-title":"Association of definitive pelvic radiation therapy with survival among patients with newly diagnosed metastatic cervical cancer","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0025","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1016\/j.prro.2018.05.010","article-title":"Definitive local therapy is associated with improved overall survival in metastatic cervical cancer","volume":"8","author":"Venigalla","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0026","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2017.10.017","article-title":"Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer","volume":"148","author":"Ning","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0027","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5114\/jcb.2022.113549","article-title":"Bevacizumab increases late toxicity in re-irradiation with image-guided high-dose-rate brachytherapy for gynecologic malignancies","volume":"14","author":"Murakami","year":"2022","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0028","unstructured":"ClinicalTrials.gov. Stereotactic body radiation therapy, tremelimumab and durvalumab in treating participants with recurrent or metastatic cervical, vaginal, or vulvar cancers. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03452332. Accessed March 31, 2022."},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0029","unstructured":"ClinicalTrials.gov. Durvalumab, tremelimumab + radiotherapy in gynecologic cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03277482. Accessed March 31, 2022."},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0030","unstructured":"ClinicalTrials.gov. SBRT and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03614949. Accessed March 31, 2022."},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0031","unstructured":"ClinicalTrials.gov. Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical\/Uterine Cancer (PRIMMO). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03192059. Accessed March 31, 2022."},{"key":"10.1016\/j.ijrobp.2022.07.002_bib0032","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijrobp.2017.06.012","article-title":"Multi-Institution Reirradiation (MIRI) Collaborative. Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: A multi-institution cohort study by the MIRI Collaborative","volume":"100","author":"Ward","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622007222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622007222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:00:42Z","timestamp":1759744842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622007222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0360301622007222"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.002","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salvage (Re)radiation in Oligometastatic and Oligorecurrent Cervical Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}